Day One Biopharmaceuticals, Inc. (DAWN)
USD 12.53
(-0.87%)
USD 12.53
(-0.87%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -146.85 Million | -109.87 Million | -48.53 Million | -13.48 Million | -4.51 Million |
| Net Income | -188.91 Million | -142.18 Million | -72.75 Million | -43.84 Million | -16.98 Million |
| Depreciation & Amortization | 383 Thousand | 531 Thousand | 199 Thousand | 155 Thousand | - |
| Deferred income taxes | -2.31 Million | - | - | - | - |
| Stock-based compensation | 39.34 Million | 27.24 Million | 13.32 Million | 526 Thousand | 111 Thousand |
| Change in working capital | 9.41 Million | 6.56 Million | 2.69 Million | -357 Thousand | 444 Thousand |
| Other non-cash items | -4.76 Million | -2.03 Million | 8 Million | 30.03 Million | 11.91 Million |
| Investing Cash Flow | 128.37 Million | -255.07 Million | -8 Million | -92 Thousand | - |
| Investments in PPE | -3.22 Million | -26 Thousand | -8 Million | -92 Thousand | - |
| Acquisitions | 3 Million | 255.04 Thousand | - | - | - |
| Investment purchases | -443.83 Million | -394.2 Million | - | - | - |
| Sales/Maturities of investments | 575.44 Million | 139.15 Million | - | - | - |
| Other Investing Activities | -3 Million | -255.04 Thousand | -8 Million | - | - |
| Financing Cash Flow | 163.99 Million | 165.9 Million | 297.12 Million | 29.97 Million | 30.9 Million |
| Debt repayment | - | - | - | - | -1 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | 1.25 Million | 642 Thousand | 318 Thousand | - | - |
| Common Stock Issuance | 163.99 Million | 165.9 Million | 167.04 Million | 29.97 Million | 29.9 Million |
| Other Financing Activities | 163.99 Million | 165.9 Million | 129.75 Million | 29.97 Thousand | 2 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | 2.31 Million | -1.48 Million | 1.54 Million | 132 Thousand | 14 Thousand |
| Inventory | - | - | - | - | - |
| Other working capital | -2.31 Million | 8.04 Million | 1.15 Million | -489 Thousand | 430 Thousand |
| Cash at beginning of period | 85.26 Million | 284.3 Million | 43.72 Million | 27.33 Million | 942 Thousand |
| Cash at end of period | 230.78 Million | 85.26 Million | 284.3 Million | 43.72 Million | 27.33 Million |
| Capital Expenditure | -3.22 Million | -26 Thousand | -8 Million | -92 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | 145.52 Million | -199.04 Million | 240.58 Million | 16.39 Million | 26.39 Million |
| Free Cash Flow | -150.07 Million | -109.9 Million | -56.53 Million | -13.58 Million | -4.51 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 37.03 Million | -4.4 Million | -62.41 Million | -54.51 Million | -188.91 Million | -46.15 Million |
| Depreciation & Amortization | 746 Thousand | 408 Thousand | 116 Thousand | 103 Thousand | 383 Thousand | 99 Thousand |
| Deferred income taxes | - | - | - | 41.57 Million | -2.31 Million | -45.79 Million |
| Stock-based compensation | 11.55 Million | 13.03 Million | 12.64 Million | 10.81 Million | 39.34 Million | 9.6 Million |
| Change in working capital | -52.2 Million | 50.73 Million | 1.21 Million | 3.8 Million | 9.41 Million | -975 Thousand |
| Other non-cash items | 53.62 Million | -96.71 Million | 9.38 Million | -43.15 Million | -4.76 Million | 46.15 Million |
| Investing Cash Flow | -67.69 Million | 17.05 Million | 89.28 Million | 30.38 Million | 128.37 Million | 88.91 Million |
| Investments in PPE | -55.72 Million | -17.12 Million | - | -8000.00 | -3.22 Million | -3.04 Million |
| Acquisitions | - | - | - | -2.99 Million | 3 Million | 3 Million |
| Investment purchases | -214.63 Million | -121.59 Million | -47.16 Million | -99.13 Million | -443.83 Million | -79.95 Million |
| Sales/Maturities of investments | 202.65 Million | 47.78 Million | 136.45 Million | 129.52 Million | 575.44 Million | 171.91 Million |
| Other Investing Activities | -55 Million | 108 Million | 89.28 Million | 2.99 Million | -3 Million | -3 Million |
| Financing Cash Flow | 200.09 Million | 1.29 Million | 48 Thousand | 597 Thousand | 163.99 Million | 115 Thousand |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | 20.94 Million | - | - | 1.25 Million | 1.25 Million | - |
| Common Stock Issuance | 178.17 Million | 1.29 Million | 48 Thousand | 597 Thousand | 163.99 Million | 115 Thousand |
| Other Financing Activities | 21.91 Million | 1.29 Million | 48 Thousand | 597 Thousand | 163.99 Million | 115 Thousand |
| Accounts receivables | 441 Thousand | -9.13 Million | - | - | - | - |
| Accounts payables | -3.42 Million | 1.66 Million | 2.2 Million | -815 Thousand | 2.31 Million | -1.17 Million |
| Inventory | -2.55 Million | -129 Thousand | - | - | - | - |
| Other working capital | -46.66 Million | 58.33 Million | -989 Thousand | 4.61 Million | -2.31 Million | 199 Thousand |
| Cash at beginning of period | 239.61 Million | 270.39 Million | 230.78 Million | 241.17 Million | 85.26 Million | 189.21 Million |
| Cash at end of period | 422.76 Million | 239.61 Million | 270.39 Million | 230.78 Million | 230.78 Million | 241.17 Million |
| Capital Expenditure | -55.72 Million | -17.12 Million | - | -8000.00 | -3.22 Million | -3.04 Million |
| Effect of forex changes on cash | - | - | - | 228.58 Million | - | -98.11 Million |
| Net cash flow / Change in cash | 183.14 Million | -30.77 Million | 39.6 Million | -10.39 Million | 145.52 Million | 51.96 Million |
| Free Cash Flow | -4.97 Million | -66.25 Million | -49.72 Million | -41.38 Million | -150.07 Million | -40.1 Million |
RNK
1780
LPX
BGS
ARYC
BAKK